Evaluation of Therapeutic Targets in Histological Subtypes of Bladder Cancer

Histologically, bladder cancer is a heterogeneous group comprising urothelial carcinoma (UC), squamous cell carcinoma, adenocarcinomas (ACs), urachal carcinomas (UrCs), and small cell neuroendocrine carcinomas (SCCs). However, all bladder cancers have been treated so far uniformly, and targeted ther...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Sophie Wucherpfennig, Michael Rose, Angela Maurer, Maria Angela Cassataro, Lancelot Seillier, Ronja Morsch, Ehab Hammad, Philipp Heinrich Baldia, Thorsten H. Ecke, Thomas-Alexander Vögeli, Ruth Knüchel, Nadine T. Gaisa
Formato: article
Lenguaje:EN
Publicado: MDPI AG 2021
Materias:
Acceso en línea:https://doaj.org/article/a764770f5cd8462992a6a09243ba1240
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:a764770f5cd8462992a6a09243ba1240
record_format dspace
spelling oai:doaj.org-article:a764770f5cd8462992a6a09243ba12402021-11-11T17:01:15ZEvaluation of Therapeutic Targets in Histological Subtypes of Bladder Cancer10.3390/ijms2221115471422-00671661-6596https://doaj.org/article/a764770f5cd8462992a6a09243ba12402021-10-01T00:00:00Zhttps://www.mdpi.com/1422-0067/22/21/11547https://doaj.org/toc/1661-6596https://doaj.org/toc/1422-0067Histologically, bladder cancer is a heterogeneous group comprising urothelial carcinoma (UC), squamous cell carcinoma, adenocarcinomas (ACs), urachal carcinomas (UrCs), and small cell neuroendocrine carcinomas (SCCs). However, all bladder cancers have been treated so far uniformly, and targeted therapy options are still limited. Thus, we aimed to determine the protein expression/molecular status of commonly used cancer targets (programmed cell death 1 ligand 1 (PD-L1), mismatch repair (MMR), androgen and estrogen receptors (AR/ER), Nectin-4, tumor-associated calcium signal transducer 2 (Tacstd2, Trop-2), epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and fibroblast growth factor receptor 3 (FGFR3)) to give first insights into whether patients with SCC, AC/UrCs, and squamous-differentiated carcinomas (Sq-BLCA) of the bladder could be eligible for targeted therapies. In addition, for MMR-deficient tumors, microsatellite instability was analyzed. We completed our own data with molecular data from The Cancer Genome Atlas (TCGA). We present ratios for each drug and cumulative ratios for multiple therapeutic options for each nonurothelial subtype. For example, 58.9% of SCC patients, 33.5% of AC/UrCs patients, and 79.3% of Sq-BLCA patients would be eligible for at least one of the analyzed targets. In conclusion, our findings hold promise for targeted therapeutic approaches in selected patients in the future, as various drugs could be applied according to the biomarker status.Sophie WucherpfennigMichael RoseAngela MaurerMaria Angela CassataroLancelot SeillierRonja MorschEhab HammadPhilipp Heinrich BaldiaThorsten H. EckeThomas-Alexander VögeliRuth KnüchelNadine T. GaisaMDPI AGarticlebladder cancertherapeutic targetsquamous-differentiated carcinomaadenocarcinomaurachal carcinomasmall cell neuroendocrine carcinomaBiology (General)QH301-705.5ChemistryQD1-999ENInternational Journal of Molecular Sciences, Vol 22, Iss 11547, p 11547 (2021)
institution DOAJ
collection DOAJ
language EN
topic bladder cancer
therapeutic target
squamous-differentiated carcinoma
adenocarcinoma
urachal carcinoma
small cell neuroendocrine carcinoma
Biology (General)
QH301-705.5
Chemistry
QD1-999
spellingShingle bladder cancer
therapeutic target
squamous-differentiated carcinoma
adenocarcinoma
urachal carcinoma
small cell neuroendocrine carcinoma
Biology (General)
QH301-705.5
Chemistry
QD1-999
Sophie Wucherpfennig
Michael Rose
Angela Maurer
Maria Angela Cassataro
Lancelot Seillier
Ronja Morsch
Ehab Hammad
Philipp Heinrich Baldia
Thorsten H. Ecke
Thomas-Alexander Vögeli
Ruth Knüchel
Nadine T. Gaisa
Evaluation of Therapeutic Targets in Histological Subtypes of Bladder Cancer
description Histologically, bladder cancer is a heterogeneous group comprising urothelial carcinoma (UC), squamous cell carcinoma, adenocarcinomas (ACs), urachal carcinomas (UrCs), and small cell neuroendocrine carcinomas (SCCs). However, all bladder cancers have been treated so far uniformly, and targeted therapy options are still limited. Thus, we aimed to determine the protein expression/molecular status of commonly used cancer targets (programmed cell death 1 ligand 1 (PD-L1), mismatch repair (MMR), androgen and estrogen receptors (AR/ER), Nectin-4, tumor-associated calcium signal transducer 2 (Tacstd2, Trop-2), epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and fibroblast growth factor receptor 3 (FGFR3)) to give first insights into whether patients with SCC, AC/UrCs, and squamous-differentiated carcinomas (Sq-BLCA) of the bladder could be eligible for targeted therapies. In addition, for MMR-deficient tumors, microsatellite instability was analyzed. We completed our own data with molecular data from The Cancer Genome Atlas (TCGA). We present ratios for each drug and cumulative ratios for multiple therapeutic options for each nonurothelial subtype. For example, 58.9% of SCC patients, 33.5% of AC/UrCs patients, and 79.3% of Sq-BLCA patients would be eligible for at least one of the analyzed targets. In conclusion, our findings hold promise for targeted therapeutic approaches in selected patients in the future, as various drugs could be applied according to the biomarker status.
format article
author Sophie Wucherpfennig
Michael Rose
Angela Maurer
Maria Angela Cassataro
Lancelot Seillier
Ronja Morsch
Ehab Hammad
Philipp Heinrich Baldia
Thorsten H. Ecke
Thomas-Alexander Vögeli
Ruth Knüchel
Nadine T. Gaisa
author_facet Sophie Wucherpfennig
Michael Rose
Angela Maurer
Maria Angela Cassataro
Lancelot Seillier
Ronja Morsch
Ehab Hammad
Philipp Heinrich Baldia
Thorsten H. Ecke
Thomas-Alexander Vögeli
Ruth Knüchel
Nadine T. Gaisa
author_sort Sophie Wucherpfennig
title Evaluation of Therapeutic Targets in Histological Subtypes of Bladder Cancer
title_short Evaluation of Therapeutic Targets in Histological Subtypes of Bladder Cancer
title_full Evaluation of Therapeutic Targets in Histological Subtypes of Bladder Cancer
title_fullStr Evaluation of Therapeutic Targets in Histological Subtypes of Bladder Cancer
title_full_unstemmed Evaluation of Therapeutic Targets in Histological Subtypes of Bladder Cancer
title_sort evaluation of therapeutic targets in histological subtypes of bladder cancer
publisher MDPI AG
publishDate 2021
url https://doaj.org/article/a764770f5cd8462992a6a09243ba1240
work_keys_str_mv AT sophiewucherpfennig evaluationoftherapeutictargetsinhistologicalsubtypesofbladdercancer
AT michaelrose evaluationoftherapeutictargetsinhistologicalsubtypesofbladdercancer
AT angelamaurer evaluationoftherapeutictargetsinhistologicalsubtypesofbladdercancer
AT mariaangelacassataro evaluationoftherapeutictargetsinhistologicalsubtypesofbladdercancer
AT lancelotseillier evaluationoftherapeutictargetsinhistologicalsubtypesofbladdercancer
AT ronjamorsch evaluationoftherapeutictargetsinhistologicalsubtypesofbladdercancer
AT ehabhammad evaluationoftherapeutictargetsinhistologicalsubtypesofbladdercancer
AT philippheinrichbaldia evaluationoftherapeutictargetsinhistologicalsubtypesofbladdercancer
AT thorstenhecke evaluationoftherapeutictargetsinhistologicalsubtypesofbladdercancer
AT thomasalexandervogeli evaluationoftherapeutictargetsinhistologicalsubtypesofbladdercancer
AT ruthknuchel evaluationoftherapeutictargetsinhistologicalsubtypesofbladdercancer
AT nadinetgaisa evaluationoftherapeutictargetsinhistologicalsubtypesofbladdercancer
_version_ 1718432194979954688